Phathom Pharmaceuticals Reports Third Quarter 2023 Results and Recent Business Updates
Third Quarter 2023 Financial Results:
- Third Quarter 2023 Financial Results:
Net loss for the third quarter ended September 30, 2023, was $43.2 million, compared to $51.1 million for third quarter 2022. - Third quarter 2023 net loss included a non-cash charge related to stock-based compensation of $6.1 million compared to $5.8 million for third quarter 2022.
- Research and development expenses for the third quarter 2023 were $12.3 million, a decrease of $6.7 million compared to $19.0 million for third quarter 2022.
- General and administrative expenses for the third quarter 2023 were $23.4 million, a decrease of $0.1 million compared to $23.5 million for third quarter 2022.